As this was a pilot exploratory study, continuous sampling over longer treatment periods in larger cohorts is required to demonstrate the utility of CSF ATP levels as a therapeutic biomarker in patients with CIDP, similar to other biomarkers such as NfL and sphingomyelin. Here, NEFL is linked to chronic inflammatory demyelinating polyradiculoneuropathy.